Donglin Sun | Prostate Cancer | Best Researcher Award

Dr. Donglin Sun | Prostate Cancer | Best Researcher Award

Southern Medical University | China

AUTHOR PROFILE

Scopus

🔬SUN DONGLIN – MEDICAL DOCTOR IN ONCOLOGY 

📚EARLY ACADEMIC PURSUITS 

Sun Donglin began his academic journey at No.1 Middle School of Fuyang, Anhui Province (2005-2008). His strong foundation in science led him to pursue a Bachelor’s Degree in Clinical Medicine at Bengbu Medical College (2008-2013), where he developed a keen interest in oncology. His dedication and passion for medical research culminated in a PhD in Oncology through the Master-Doctor Continuous Program at the Affiliated Cancer Hospital of Guangzhou Medical University (2018-2023). He was recognized as an “Outstanding Graduate Student” and “Excellent Graduate”, a testament to his academic excellence and research contributions.

🏥PROFESSIONAL ENDEAVORS 

Sun Donglin’s clinical training and professional career reflect a steady progression in expertise:

  • 2013 – 2016: Surgical Resident, Third Affiliated Hospital of Sun Yat-sen University – Gained hands-on experience in surgical oncology.
  • 2016 – 2018: Urology Resident Physician, Shenzhen Hospital of Southern Medical University – Developed a specialization in urological oncology.
  • 2023 – Present: Urology Associate Chief Physician, Shenzhen Hospital of Southern Medical University – Achieved Associate Chief Physician Certification in 2020, demonstrating his leadership in urologic oncology and clinical excellence.

🔍RESEARCH FOCUS 

Sun Donglin’s research focuses on two critical areas in oncology:

  1. Mechanisms of Non-Canonical NF-κB Signaling in Renal Fibrosis – Investigating how alternative pathways of NF-κB contribute to fibrosis, which has significant implications for kidney disease treatments.
  2. Drug Resistance Mechanisms in Prostate Cancer – Exploring molecular resistance pathways in prostate cancer to enhance therapeutic strategies and overcome treatment barriers.

💡CONTRIBUTIONS TO SCIENTIFIC RESEARCH 

Sun Donglin has led and participated in several high-impact research projects:

  • Principal Investigator:

    • National Natural Science Foundation of China (Youth Program)300,000 RMB (2025-2027) (Approval No.: 82400789)
    • Guangdong Provincial Medical Science and Technology Research Fund10,000 RMB (2024-2026) (Approval No.: A2024317)
    • Southern Medical University National Natural Science Foundation Cultivation Program100,000 RMB (2024-2026) (Approval No.: 23H3AGZR02)
  • Key Participant in Major Research Projects:

    • National Natural Science Foundation of China Major Research Program Cultivation Project680,000 RMB (2020-2022) (Approval No.: 91949102)
    • National Natural Science Foundation of China General Program570,000 RMB (2019-2022) (Approval No.: 81874095)

🌍IMPACT AND INFLUENCE 🌍

Sun Donglin’s research has contributed to a deeper understanding of renal fibrosis mechanisms and drug resistance in prostate cancer. His work has the potential to improve therapeutic interventions and patient outcomes, particularly in treatment-resistant prostate cancer cases. His collaborations in major national projects highlight his role as an emerging leader in oncological research.

🏅ACADEMIC CITES AND RECOGNITION 

  • Recognized as an Outstanding Graduate Student and Excellent Graduate during his PhD.
  • His research findings are gaining recognition in top-tier oncology journals, further solidifying his influence in the field.
  • Contributions to multi-million RMB-funded research projects, showcasing his ability to secure competitive grants.

🌱LEGACY AND FUTURE CONTRIBUTIONS 

Sun Donglin’s work will shape the future of oncology therapeutics and urological oncology. His research on non-canonical NF-κB signaling could unlock new pathways for renal fibrosis treatment, while his studies on prostate cancer drug resistance could lead to novel therapeutic strategies.

Moving forward, he aims to:
Expand research collaborations internationally to enhance the impact of his studies.
Develop translational therapies targeting NF-κB signaling in fibrosis and prostate cancer.
Mentor young oncologists and researchers to foster the next generation of medical scientists.

🌍CONCLUSION 

Dr. Sun Donglin is a rising leader in oncology research and urological oncology, with a strong foundation in both clinical practice and scientific innovation. His expertise in non-canonical NF-κB signaling in renal fibrosis and drug resistance in prostate cancer has positioned him as a key contributor to the advancement of cancer therapeutics.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Serum RelB is correlated with renal fibrosis and predicts chronic kidney disease progression
    Authors: Sun, D., Xie, N., Wang, X., Wu, W., Li, X. Y., Chen, X., Qian, G., Li, C., Zhang, H., Jiang, Y., Ye, D., Liu, D., Hu, Y., Wang, J., Chen, W., Zhao, Q., Zeng, M., Zhang, J., Wang, L., & Zhang, X
    Journal: Clinical and Translational Medicin
    Year: 2021

 

  • Title: B-cell-derived IL-10 promotes allergic sensitization in asthma regulated by Bcl-3.
    Authors: Qian, G., Jiang, W., Sun, D., Sun, Z., Chen, A., Fang, H., Wang, J., Liu, Y., Yin, Z., Wei, H., Fang, H., & Zhang, X.
    Journal: Cellular & Molecular Immunology
    Year: 2023

 

  • Title: Development of RelB-Targeting Small Molecule Inhibitors of Non-canonical NF-κB Signaling with Antitumor Efficacy
    Authors: Li, C., Wei, S., Sun, D., Yang, Z., Wang, Q., Lin, H., Zhang, H., Hu, Y., Liu, D., Ye, D., Tao, Y., Liu, Z., Xu, Z., Li, B., Li, L., Zhang, J., Chen, X., Xie, N., Shi, Y., Liu, S., Liu, Y., Jiang, Y., Zhu, W., & Zhang, X.
    Journal: Molecular Therapy
    Year: 2025

 

  • Title: LKB1 activated by NaB inhibits the IL-4/STAT6 axis and ameliorates renal fibrosis through the suppression of M2 macrophage polarization.
    Authors: Liang, W., Wu, H., Long, Q., Lin, H., Lv, X., Ma, W., Wu, T., Ai, L., Zheng, Q., Guo, J., Chen, X., Guo, J., & Sun, D..
    Journal: Life Sciences
    Year: 2025

 

  • Title: Integrative analysis of potential diagnostic markers and therapeutic targets for glomerulus-associated diabetic nephropathy based on cellular senescence
    Authors: Sun, D., Wei, S., Wang, D., Zeng, M., Mo, Y., Li, H., Liang, C., Li, L., Zhang, J. W., & Wang, L
    Journal: Frontiers in Immunology
    Year: 2023

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Kansai Medical University Hospital | Japan

AUTHOR PROFILE

Scopus

ORCID Id

🧑‍🎓 EARLY ACADEMIC PURSUITS 📚

Dr. Yuta Yamanaka embarked on his medical journey with a deep interest in oncology, focusing particularly on thoracic diseases. He completed his Medical Degree from a prestigious Japanese university, demonstrating a clear passion for cancer research, specifically targeting lung cancer. His early education laid a robust foundation in both clinical medicine and research methodologies, setting the stage for his future breakthroughs in thoracic oncology.

🩺 PROFESSIONAL ENDEAVORS 🏥

Dr. Yamanaka is a renowned thoracic oncologist at Kansai Medical University Hospital, one of Japan’s leading institutions for cancer treatment. His medical career is marked by his dedication to patient care, coupled with his pursuit of cutting-edge research in lung cancer. As a departmental leader, Dr. Yamanaka has played a crucial role in developing new protocols for the management and treatment of thoracic malignancies. His efforts have enhanced both the clinical approach and patient outcomes at the hospital.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LUNG CANCER🔍

Dr. Yamanaka’s primary research focus is on lung cancer, particularly in the early detection, diagnosis, and treatment of this aggressive disease. He is actively involved in clinical trials exploring novel therapeutic strategies, including targeted therapies and immunotherapy. His research has contributed to the development of new approaches to personalize treatment for lung cancer patients, making strides in precision oncology.

Additionally, Dr. Yamanaka has worked on improving the understanding of tumor biology in thoracic cancers and has published extensively on the molecular mechanisms underlying lung cancer progression.

🌍 IMPACT AND INFLUENCE 💡

Dr. Yamanaka’s work has not only impacted the lives of his patients but has also influenced the broader field of thoracic oncology. His clinical trials have pushed the boundaries of what is possible in lung cancer treatment, helping to establish new standards of care. Moreover, his contributions to the understanding of lung cancer at a molecular level have provided other researchers with critical insights, fostering global collaborations.

🏆 ACADEMIC CITES AND RECOGNITION 📜

Dr. Yamanaka has been widely cited in prestigious oncology journals for his pioneering work on lung cancer. His research has garnered international recognition, with citations numbering in the thousands, reflecting his influence in both clinical and academic spheres. He frequently presents his findings at global oncology conferences and serves as a reviewer for leading medical journals.

🔮 LEGACY AND FUTURE CONTRIBUTIONS 🌟

Looking forward, Dr. Yamanaka is poised to continue his groundbreaking work in thoracic oncology. His future research is expected to delve deeper into early-stage lung cancer detection, with the goal of significantly improving survival rates. He remains dedicated to exploring new frontiers in personalized medicine and further enhancing treatment outcomes for lung cancer patients through novel therapeutics and multimodal therapies.

Dr. Yamanaka’s legacy will undoubtedly be marked by his relentless pursuit of innovation and excellence in the treatment of thoracic cancers, securing his place as a leading figure in the global fight against lung cancer.

Dr. Yuta Yamanaka’s work in the field of lung cancer research and clinical care makes him a vital contributor to both Japanese and international oncology communities. His dedication continues to shape the future of thoracic oncology, with the promise of many more contributions to come.

✨ CONCLUSION 🎯

Dr. Yuta Yamanaka stands as a trailblazer in the field of thoracic oncology, particularly in his groundbreaking research and clinical advancements in lung cancer. His early academic pursuits laid a solid foundation for an impressive career marked by innovation, dedication, and compassion. As a respected leader at Kansai Medical University Hospital, his efforts in advancing targeted therapies, improving patient outcomes, and deepening the global understanding of lung cancer have left an indelible mark on both the medical community and the lives of countless patients.

 

📊🔬NOTABLE PUBLICATION:

 

    • Clinical significance of factor XIII activity and monocyte-derived microparticles in cancer patients
      • Authors: Sawai, Y., Yamanaka, Y., Nomura, S.
      • Journal: Vascular Health and Risk Management
      • Year: 2020

     

    • Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study
      • Authors: Takeda, T., Yamada, T., Kunimatsu, Y., Kurata, T., Takayama, K.
      • Journal: Cancers
      • Year: 2023

     

    • Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older
      • Authors: Yagishita, S., Yamanaka, Y., Kurata, T., Mizugaki, H., Hamada, A.
      • Journal: Clinical Pharmacology and Therapeutics
      • Year: 2024

     

    • Paraneoplastic Neurological Syndrome-associated Antibody-positive Small-cell Lung Cancer Diagnosed with Preceding Neurological Symptoms: a Case Series 
      • Authors: Okazaki, Y., Yoshioka, H., Kamisako, K., Yamanaka, Y., Kurata, T.
      • Journal: Japanese Journal of Lung Cancer
      • Year: 2024

     

    • Investigation of a practical assessment index to capture the clinical presentation of cachexia in patients with lung cancer
      • Authors: Katsushima, U., Hase, K., Fukushima, T., Imai, Y., Kurata, T.
      • Journal: Japanese Journal of Clinical Oncology
      • Year: 2024